Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 7/20 | 0.56 |
| ▸ | ABL1 | P00519 | 2/20 | 0.56 |
| ▸ | IDE | P14735 | 2/20 | 0.56 |
| ▸ | RIN1 | Q13671 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | NR2E3 | Q9Y5X4 | 1/20 | 0.43 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.43 |
| ▸ | HLCS | P50747 | 6/20 | 0.36 |
| ▸ | CA12 | O43570 | 3/20 | 0.32 |
| ▸ | CA1 | P00915 | 3/20 | 0.32 |
| ▸ | CA2 | P00918 | 3/20 | 0.32 |
| ▸ | CA9 | Q16790 | 3/20 | 0.32 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14563008 | 1.00 | TDP1 (0.56) | TDP1ABL1IDERIN1MEN1 | |
| SCHEMBL19751695 | 1.00 | TDP1 (0.56) | TDP1ABL1IDERIN1MEN1 | |
| SCHEMBL13049589 | 1.00 | TDP1 (0.56) | TDP1ABL1IDERIN1MEN1 | |
| SCHEMBL19751702 | 0.89 | TDP1 (0.48) | TDP1ABL1IDERIN1MEN1 | |
| SCHEMBL4965653 | 0.89 | TDP1 (0.48) | TDP1ABL1IDERIN1MEN1 | |
| SCHEMBL3793600 | 0.86 | TDP1 (0.56) | TDP1ABL1IDERIN1MEN1 | |
| SCHEMBL4970357 | 0.85 | TDP1 (0.39) | TDP1ABL1IDERIN1MEN1 | |
| SCHEMBL19751691 | 0.85 | TDP1 (0.39) | TDP1ABL1IDERIN1MEN1 | |
| SCHEMBL18501097 | 0.85 | TDP1 (0.39) | TDP1ABL1IDERIN1MEN1 | |
| SCHEMBL4965402 | 0.84 | TDP1 (0.59) | TDP1ABL1IDERIN1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 439 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119395003-A | Kit, microfluidic device and method for performing biotin assays | 美国西门子医学诊断股份有限公司 | 2025-02-07 | — | — | CN | claimed |
| US-20250027947-A1 | KITS, MICROFLUIDICS DEVICES, AND METHODS FOR PERFORMING BIOTIN ASSAYS | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2025-01-23 | — | — | US | claimed |
| CN-112424589-B | Kit, microfluidic device and method for performing biotin assays | 美国西门子医学诊断股份有限公司 | 2025-01-14 | — | — | CN | claimed |
| EP-3830556-B1 | KITS, MICROFLUIDICS DEVICES, AND METHODS FOR PERFORMING BIOTIN ASSAYS | SIEMENS HEALTHCARE DIAGNOSTICS INC (US) | 2024-11-13 | — | — | EP | claimed |
| US-12140596-B2 | Kits, microfluidics devices, and methods for performing biotin assays | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2024-11-12 | — | — | US | claimed |
| EP-4416303-A1 | A MICROSPHERE COMPRISING A FIRST MATERIAL AND A SECOND MATERIAL | Blink AG (DE) | 2024-08-21 | — | — | EP | claimed |
| CN-118510909-A | Microsphere comprising a first material and a second material | 布林克公司 | 2024-08-16 | — | — | CN | claimed |
| US-20240084354-A1 | MEANS AND METHODS FOR REGULATING INTRACELLULAR TRAFFICKING OF SECRETORY OR CELL MEMBRANE-ANCHORED PROTEINS OF INTEREST | HONING BIOSCIENCES (FR) | 2024-03-14 | — | — | US | claimed |
| EP-4244240-A1 | MEANS AND METHODS FOR REGULATING INTRACELLULAR TRAFFICKING OF SECRETORY OR CELL MEMBRANE-ANCHORED PROTEINS OF INTEREST | Honing Biosciences (FR) | 2023-09-20 | — | — | EP | claimed |
| WO-2023154852-A1 | ANTIBODY BARCODED BEADS AND USES THEREOF | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2023-08-17 | — | — | WO | claimed |
| WO-2000072802-A2 | WATER SOLUBLE MULTI-BIOTIN-CONTAINING COMPOUNDS | UNIVERSITY OF WASHINGTON (US) | 2000-12-07 | — | — | WO | claimed |
| US-6075010-A | Small molecular weight ligand-hexose containing clearing agents | NEORX CORPORATION (US) | 2000-06-13 | — | — | US | claimed |
| EP-0743956-A4 | PRETARGETING METHODS AND COMPOUNDS | NEORX CORP (US) | 1999-03-24 | — | — | EP | claimed |
| EP-0743956-A1 | PRETARGETING METHODS AND COMPOUNDS | NeoRx (US) | 1996-11-27 | — | — | EP | claimed |
| EP-0717848-A1 | BIOTIN-ANALOG CONJUGATED ANTIBODIES FOR POSITIVE CELL SELECTION AND RELEASE | BAXTER INTERNATIONAL INC. (US) | 1996-06-26 | — | — | EP | claimed |
| WO-1995015978-A1 | PRETARGETING METHODS AND COMPOUNDS | NEORX CORPORATION (US) | 1995-06-15 | — | — | WO | claimed |
| WO-1995007466-A2 | BIOTIN-ANALOG CONJUGATED ANTIBODIES FOR POSITIVE CELL SELECTION AND RELEASE | BAXTER INTERNATIONAL INC. (US) | 1995-03-16 | — | — | WO | claimed |
| EP-0088542-B1 | SKIN TREATMENT COMPOSITION | UNILEVER N.V. (NL) | 1988-05-11 | — | — | EP | claimed |
| US-4529587-A | Using biotin antagonist | LEVER BROTHERS COMPANY (US) | 1985-07-16 | — | — | US | claimed |
| EP-0088542-A2 | Skin treatment composition | UNILEVER N.V. (NL) | 1983-09-14 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240084354-A1 | MEANS AND METHODS FOR REGULATING INTRACELLULAR TRAFFICKING OF SECRETORY OR CELL MEMBRANE-ANCHORED PROTEINS OF INTEREST | PHAX, SCAMP2, YIPF5 | TDP1 2678/4885ABL1 4402/4885IDE 3003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.